Home / Health / Local patients injected in trials with Modernes COVID-19 vaccine candidate

Local patients injected in trials with Modernes COVID-19 vaccine candidate



Local volunteers have received their first injections in the large, final stage of a COVID-19 vaccine candidate created by the Cambridge-based Modern and National Institute of Allergy and Infectious Diseases. A spokesman for Brigham and Women’s Hospital, one of dozens of sites conducting the Phase 3 trial, confirmed on Wednesday that doctors there had administered the first injections to volunteers. Early studies control side effects and try to determine how participants respond to different doses, but only the phase 3 study is large enough to show if the vaccine candidate works. The first injection in the Phase 3 study was given in Savannah, Georgia. Volunteers do not know if they are getting the right shot or a placebo. After two doses, researchers will carefully track which group experiences more infections as they carry out their daily routines, especially in areas where the virus is still spreading uncontrollably. The vaccine candidate was created based on the genetic sequence of the new coronavirus, which was shared by the Chinese government. Moderna said its researchers worked with investigators from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases to identify the messenger̵

7;s RNA vaccine. There is no chance that the participants can be infected from the shots because they do not contain the coronavirus itself. Using data from the Phase 1 study, which began in March, Moderna said it had selected a dose of 100 micrograms and manufactured the amount of vaccine required to start the Phase 3 study. The 45 adult participants in the phase 1 study are still being tracked, but the company reported positive early results in May. When it was ready, Moderna said the results of the first study would be submitted by the National Institutes of Health to a peer-reviewed clinical publication. Meanwhile, Moderna announced on Wednesday that its phase 2 study of the potential vaccine with 600 volunteers was now fully enrolled.

Local volunteers have received their first injections in the large, final stage of a COVID-19 vaccine candidate created by the Cambridge-based Modern and National Institute of Allergy and Infectious Diseases.

A spokesman for Brigham and Women’s Hospital, one of dozens of sites conducting the Phase 3 trial, confirmed on Wednesday that doctors there had administered the first injections to volunteers.

Early studies check for side effects and try to determine how participants respond to different doses, but only the phase 3 study is large enough to show if the vaccine candidate works.

The first injection in the Phase 3 study was given in Savannah, Georgia.

Volunteers do not know if they are getting the right shot or a placebo. After two doses, researchers will track which group experiences more infections as they carry out their daily routines, especially in areas where the virus is still spreading uncontrollably.

The vaccine candidate was created based on the genetic sequence of the new coronavirus, which was shared by the Chinese government. Moderna said its researchers worked with investigators from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases to identify the messenger’s RNA vaccine. There is no chance that the participants may be infected from the images because they do not contain the coronavirus itself.

Using data from the Phase 1 study, which began in March, Moderna said it had selected a dose of 100 micrograms and manufactured the amount of vaccine required to start the Phase 3 study.

The 45 adult participants in the phase 1 study are still being tracked, but the company reported positive early results in May. When it was ready, Moderna said the results of the first study would be submitted by the National Institutes of Health to a peer-reviewed clinical publication.

At the same time, Moderna announced on Wednesday that its phase 2 study of the potential vaccine with 600 volunteers was now fully included.


Source link